The invention provides a drug capable of simultaneously reducing bleeding and microvascular occlusion risks. Specifically, the present invention provides a composition comprising (a) a therapeuticallyeffective amount of a first active component, wherein the first active component is clopidogrel or a pharmaceutically acceptable salt thereof; (b) a therapeutically effective amount of a second active component, wherein the second active component is salvianolic acid B or the pharmaceutically acceptable salt thereof; and (c) a therapeutically effective amount of a third active component, which isginsenoside Rg1 or the pharmaceutically acceptable salt thereof. The first active component, the second active component and the third active component can generate a two-way synergistic protection effect, capillary blockage can be effectively reduced, bleeding can be effectively prevented, the dosage of a single medicine is reduced, and the toxicity of the medicine is reduced.